Compare Cenovus Energy Inc (CVE) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Johnson & Johnson — how do they compare? Cenovus Energy Inc trades at $31.58 (market cap $57.90B), while Johnson & Johnson trades at $260.33 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 10.7× Cenovus Energy Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Johnson & Johnson for 129 Days on average.
| CVE | JNJ | |
|---|---|---|
Market Cap | $57.90B | $618.09B |
Volume | 7,863,588 | 6,050,983 |
Sector | Energy | Health |
52-Week High | $33.92 | $278.43 |
52-Week Low | $15.85 | $186.00 |
Typical Hold Time | 46 Days | 129 Days |
Enterprise Value | $63.84B | $646.37B |
Dividend Yield | 1.97% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.53, up 2.94% with a bullish technical signal and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, net income margin of 11.48%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight the company's attractive valuation and growth prospects in the energy sector.
Outlook remains positive with projected 2026 revenue of $58.0B and net income of $6.7B, though investors should monitor oil price volatility and execution risks. Analyst consensus leans bullish with 11 buy ratings versus 1 sell, while technical indicators suggest potential resistance near $32.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
